CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 58 enrolled
Drug / intervention
salsalate +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00760019
NCT00760019Phase 3Completed
CompareCT.gov

Inflammation and Vascular Function in Atherosclerosis

Brigham and Women's Hospital·interventional·Posted Sep 25, 2008·Updated May 16, 2017

In Brief

A Phase 3 clinical trial evaluating salsalate and placebo for Atherosclerosis. Completed, enrolled 58 participants across 1 site.

Detailed Summary

The purpose of this study is to determine whether reducing inflammation in blood vessels with an aspirin-like drug called salsalate will improve blood vessel function.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtherosclerosis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 25, 2008
Enrollment StartAug 1, 2005
Primary CompletionOct 1, 2009
Study CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4.2 yearsPosted 17.8 years ago

Interventions

salsalatedrug

1.5 grams orally 3 times daily

placebodrug

matching placebo